Understanding the inhibition of antigen-specific T cells by the KSHV protein vOX2 and its cellular counterpart, CD200

了解 KSHV 蛋白 vOX2 及其细胞对应物 CD200 对抗原特异性 T 细胞的抑制

• 批准号: G0800154/1
• 负责人: David Blackbourn
• 金额: $ 51.44万
• 依托单位: University of Birmingham
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2008
• 资助国家: 英国
• 起止时间: 2008 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0800154%2F1
• 关键词: Understanding; inhibition; antigen; specific; cells

Kaposi?s sarcoma-associated herpesvirus (KSHV) is the probable cause of Kaposi?s sarcoma (KS), a cancer affecting AIDS patients and the most prevalent tumour in Africa. KSHV interferes with the immune response, which normally helps to prevent viral diseases. This interference presumably helps the virus to become established in the infected person, leading to disease. Our work suggests that one KSHV protein, called vOX2, is responsible for this immune interference since it suppresses the immune response: it is ?anti-inflammatory?, and in the present proposal we want to understand how vOX2 achieves this activity. Understanding the function of vOX2 could help understand the host?s immune response to infection and lead to new types of therapy for certain human diseases.Normally, immune responses are beneficial, but when their control goes wrong, they can attack the body they are supposed to defend and cause inflammatory diseases such as contact dermatitis, rheumatoid arthritis, psoriasis and lung conditions like chronic obstructive pulmonary disease (COPD). The processes behind these diseases are quite well understood. We believe that vOX2, or derivatives, offers a new solution to treating these sorts of inflammatory diseases and the outcome of our proposed studies could enable the development of new types of anti-inflammatory drugs.The data generated by our studies will be published in scientific journals, but also communicated to a more general audience through Dr. Blackbourn?s engagement in science communication with the public. Typically, this involves talking to fund-raising groups and high school students about viruses and disease, including his research.

卡波西？肉瘤相关疱疹病毒（KSHV）是卡波西？S肉瘤（KS）是一种影响艾滋病患者的癌症，也是非洲最流行的肿瘤。KSHV干扰免疫反应，这通常有助于预防病毒性疾病。这种干扰可能有助于病毒在感染者体内建立，导致疾病。我们的工作表明，一种称为vOX2的KSHV蛋白质负责这种免疫干扰，因为它抑制免疫反应：它是？消炎药在本发明中，我们想了解vOX 2如何实现这种活性。了解vOX2的功能有助于了解宿主？正常情况下，免疫反应是有益的，但当它们的控制出错时，它们可以攻击它们应该保护的身体并引起炎症性疾病，如接触性皮炎，类风湿性关节炎，牛皮癣和肺部疾病，如慢性阻塞性肺病（COPD）。这些疾病背后的过程是非常清楚的。我们相信vOX2或其衍生物为治疗这类炎症性疾病提供了一种新的解决方案，我们提出的研究结果可能有助于开发新型抗炎药物。我们的研究产生的数据将发表在科学期刊上，但也将通过Blackbourn博士向更广泛的受众传达。与公众进行科学交流。通常情况下，这包括与筹款团体和高中生谈论病毒和疾病，包括他的研究。